-

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the Gilead Foundation, supports organizations addressing food insecurity in California, North Carolina, New Jersey, Maryland, and Washington, D.C.

The funding focuses on reducing barriers to fresh food in vulnerable communities where food insecurity rates remain highest. Funding supports innovative food sourcing and distribution models, and integrated services to connect families with nutrition education, workforce training, and benefits enrollment.

“There is a deep connection between food security and health,” said Shreya Jani, Senior Vice President of Public Affairs, Gilead Sciences and Board Member, Gilead Foundation. “Food insecurity is linked to a wide range of health risks, including chronic conditions, infectious diseases, and other serious illnesses. Through Gilead Foundation Healing Hunger, we are partnering with organizations that provide education, infrastructure, training and more to make a real impact and improve health outcomes.”

Food insecurity is closely tied to poorer health outcomes, including diabetes, hypertension, obesity, and depression, as well as developmental delays and long-term health issues for children. The Gilead Foundation grants will be used to pilot and scale solutions including mobile pantries, produce recovery efforts, urban farming initiatives, and school-centered distribution programs, with the goal to strengthen local food systems and improve food stability for families.

“The California Association of Food Banks, in partnership with the five Bay Area food banks, is grateful for the Gilead Foundation’s investment in our collaborative sourcing model,” said Stacia Hill Levenfeld, Chief Executive Officer, California Association of Food Banks. “This funding will expand access to culturally relevant food, strengthen local food systems, and improve long-term community health.”

Key Facts:

  • USDA data shows that adults in very low food-secure households experience substantially higher rates of chronic conditions, including hypertension (36.4% vs. 29.1%) and diabetes (9.6% vs. 4.3%).
  • Additional USDA analysis from 2019–22 found that the predicted prevalence of key chronic diseases was 1.9 to 9.5 percentage points higher among adults in very low food-secure households compared with those in high food-secure households.
  • Children living in food-insecure households face significantly worse health outcomes, including higher rates of asthma and depressive symptoms, nearly double the likelihood of emergency department visits, and a 179% increase in forgone medical care, underscoring the urgent need to address food insecurity as a public health priority.

Grant recipients include:

  • California Association of Food Banks Bay Area Collaborative including the San Francisco-Marin Food Bank, Alameda County Community Food Bank, Second Harvest of Silicon Valley, Food Bank of Contra Costa and Solano, and Redwood Empire Food Bank to scale an equity-driven sourcing model that distributes 1.2 million pounds of culturally relevant produce while lowering food bank costs and supporting minority-owned farms.
  • Los Angeles Regional Food Bank to support a year-round mobile pantry program delivering 2.5 million pounds of food to communities across Los Angeles County.
  • Social Justice Learning Institute to distribute 850,000 pounds of fresh produce while expanding community-led education and urban farming efforts in Inglewood, CA.
  • Food Forward to aid a produce recovery program that redirects 833,000 pounds of fresh food and reduces waste and emissions in Southern California.
  • Food Bank of Central and Eastern North Carolina to support the distribution of 17 million pounds of food through 600 partner agencies.
  • Community Food Bank of New Jersey to deliver 2.28 million pounds of food to children while expanding workforce training and benefits enrollment programs.
  • Interfaith Food Pantry Network to support 2.3 million pounds of year-round food distribution and food recovery efforts for families in Morris County, NJ.
  • Capital Area Food Bank to expand Mobile Market sites in Washington, DC and to provide more than 1.2 million pounds of food through 170 schools.
  • Maryland Food Bank to support school pantries that deliver 2.4 million pounds of food through 170 schools.

The Gilead Foundation's investment in Gilead Foundation Healing Hunger is part of its broader commitment to supporting communities where Gilead employees live and work. In 2024, the Foundation contributed $21.5 million to organizations committed to advance programs that promote education, health equity, and community resilience.

About the Gilead Foundation

The Gilead Foundation is a nonprofit organization that works to create a thriving health ecosystem. The Gilead Foundation takes a holistic approach to mitigate the root causes of health inequities by providing resources to organizations that empower people with the skills to be their own best advocate and create systems of support that strengthen communities, classrooms and workplaces.

About Gilead Sciences

Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

Contacts

Samantha Stokes-Granberry, Media
public_affairs@gilead.com

Jacquie Ross, Investors
investor_relations@gilead.com

Gilead Sciences, Inc.

NASDAQ:GILD

Release Versions

Contacts

Samantha Stokes-Granberry, Media
public_affairs@gilead.com

Jacquie Ross, Investors
investor_relations@gilead.com

More News From Gilead Sciences, Inc.

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people livin...

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non-inferior to multi-tablet regimens. Gilead plans to file th...

Gilead Provides Update on Phase 3 ASCENT-07 Study

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 criteria. Overall survival is a key secondary endpoi...
Back to Newsroom